CASE REPORT

Hypophosphataemia: an important cause of collapse

David M Williams,^{1,2} Natasha Shrikrisnapalasuriyar,¹ David E Price,¹
Jeffrey W Stephens^{1,2}

¹Department of Diabetes and Endocrinology, Morriston Hospital, Swansea, UK
²Diabetes Research Unit, College of Medicine, Swansea University, Swansea, UK

Correspondence to

Dr David M Williams,
david.williams@doctors.org.uk

Accepted 30 June 2018

SUMMARY

We present a case of a 44-year-old man, civil servant, who presented to the emergency department (ED) following an episode of collapse. He was usually fit and well and while at work he had developed a headache with pins and needles over his face and subsequently collapsed. On arrival to ED, he had a Glasgow Coma Scale (GCS) of 4/15. There was no history of note apart from being prescribed citalopram for depression. Laboratory investigations revealed severe hypophosphataemia (phosphate 0.19 mmol/L) and no other electrolyte abnormality. He was commenced on intravenous phosphate and his GCS improved to 15 within 4 hours. Further investigations revealed no cause for his severe hypophosphataemia and repeat bloods in clinic follow-up showed a normal phosphate level.

BACKGROUND

Collapse is one of the most common presenting complaints during the acute medical take and is typically a consequence of cardiac or neurological disturbance. Despite the common nature of this complaint, it is often challenging to diagnose the cause of collapse in some patients.

Electrolyte disorders can affect cardiac and neurological function, resulting in collapse. Electrolyte disorders known to cause collapse include hypocalcaemia,¹ hypercalcaemia,² hypokalaemia,³ hyperkalaemia,⁴ hyponatraemia⁵ and hypernatraemia.⁶ However, hypophosphataemia is not commonly associated with collapse, although previous reports associate hypophosphataemia with acute confusion,⁷ visual hallucinations⁸ and Wernicke's encephalopathy.⁹ Hypophosphataemia has also been associated with seizures¹⁰ and coma,¹¹ though importantly these cases were also associated with refeeding and alcohol abuse, respectively.

In this case report, we describe a patient who presented with collapse caused by severe hypophosphataemia with no other significant comorbidity.

CASE PRESENTATION

A 44-year-old man who worked for the Driving and Vehicle Licensing Agency (DVLA) presented to the emergency department (ED) with a collapse. He was normally fit and well and was prescribed citalopram for depression. He did not smoke or drink alcohol and took no illicit drugs. He had developed a headache associated with pins and needles over his face and left arm while at work, and subsequently collapsed. When the paramedics arrived, he had a

GCS of 15, blood pressure 144/78, capillary blood glucose 11.8 mmol/L and was afebrile.

On arrival to the ED, his GCS had dropped to 4/15. Other than his reduced GCS, the physical examination was unremarkable and there were no signs of neck rigidity or rash.

INVESTIGATIONS

His admission ECG showed normal sinus rhythm. The full blood count and electrolytes were normal. His bone profile demonstrated a calcium level of 2.51 mmol/L (normal range 2.20–2.60 mmol/L) and a magnesium level of 0.77 mmol/L (normal range 0.70–1.00 mmol/L). The only biochemical abnormality found was a low serum phosphate of 0.19 mmol/L (normal range 0.80–1.50 mmol/L). During the admission, 5 days following replacement of his serum phosphate, his urinary phosphate level was noted to be normal. A CT head taken on admission was also unremarkable.

Further investigations including serum parathyroid hormone, vitamin D, immunoglobulins and antitissue transglutaminase antibodies were normal. Echocardiogram showed no evidence of left ventricular dysfunction or valvular disturbance. [Figure 1](#) demonstrates his serum phosphate level from hospital admission to clinic follow-up.

DIFFERENTIAL DIAGNOSIS

The differential diagnosis included:

- Possible seizure with a prodromal episode of pins and needles over the body.
- Possible encephalitis, given his sudden history of collapse and reduced GCS.
- Cardiac syncope should also be considered, though this young adult had an ECG demonstrating normal sinus rhythm and a normal corrected QT interval.

TREATMENT

He was commenced on a 500 mL intravenous infusion of phosphate polyfusor over 12 hours. By the next day, his phosphate had increased from 0.19 mmol/L to 1.13 mmol/L. While having this infusion, his GCS improved to 15 within 4 hours and he remained alert throughout the remainder of the admission. During his admission to hospital, he underwent further testing including Holter monitoring which showed sinus rhythm and an echocardiogram demonstrating good ventricular function with an ejection fraction of 55%. His biochemical markers were within normal limits and his serum phosphate was measured daily. By day 4 of his

© BMJ Publishing Group Limited. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Williams DM, Shrikrisnapalasuriyar N, Price DE, et al. *BMJ Case Rep* Published Online First: [please include Day Month Year]. doi:10.1136/bcr-2018-225821

Graph showing the course of phosphate level over the hospital admission

Figure 1 The patient's serum phosphate level from admission to clinic follow-up.

hospital admission, he was started on oral phosphate sandoz as his phosphate decreased to 0.75 mmol/L and had returned to normal 3 days afterwards. The cause of his hypophosphataemia remains unknown.

OUTCOME AND FOLLOW-UP

After 8 days of admission, he was discharged from hospital with a serum phosphate of 1.22 mmol/L. He was followed up in the endocrine clinic 4 weeks later with repeat blood tests which were within normal limits. His phosphate level since the admission has been within normal limits with no subsequent readmission. The cause of his hypophosphataemia remains unknown. There was no evidence of refeeding syndrome or alcoholism and his further biochemical investigations remained normal.

DISCUSSION

Hypophosphataemia is a relatively common electrolyte disturbance in certain subgroups, prevalent in up to 3.1% of hospital inpatients, up to 33.9% of patients admitted to intensive care units, up to 30.4% with chronic alcoholism and up to 80% of septic patients.¹² Mild (0.65–0.79 mmol/L) and moderate (0.32–0.64 mmol/L) hypophosphataemia may present with non-specific symptoms such as generalised muscle weakness, myalgia and fatigue. Patients with severe hypophosphataemia (<0.32 mmol/L) may present with serious sequelae such as confusion, hallucinations and seizures. As a result of its non-specific symptoms, this electrolyte disturbance is often not considered and the patient's symptoms subsequently misdiagnosed.¹³

The treatment of hypophosphataemia can be achieved with oral, intravenous or intradialytic therapy. The treatment approach is determined by the serum phosphate level and the patient's symptoms. Generally, oral replacement would best be given to those with mild to moderate symptoms and levels of hypophosphataemia, while patients with severely low phosphate and/or symptoms, or who are unable to take phosphate orally would receive intravenous replacement. It is important to closely monitor the patient, as intravenous phosphate administration

can provoke ECG changes, seizures, life-threatening hypocalcaemia and hyperkalaemia.¹³

There are many causes of hypophosphataemia, including malnutrition (refeeding syndrome, anorexia nervosa, malabsorption, alcohol abuse), endocrine (hyperparathyroidism), renal (X-linked hypophosphatemia, hereditary hypophosphatemic rickets, Fanconi syndrome), respiratory alkalosis (sepsis, salicylate poisoning, anxiety) and medications (cisplatin, tetracyclines, aminoglycosides, antiretrovirals).¹³ Rarely, hypophosphataemia is caused by oncogenic osteomalacia, in which elevated serum fibroblast growth factor 23 (FGF 23) levels induce hypophosphataemia by binding proximal tubule cells, thereby reducing renal phosphate reabsorption.¹⁴ Typically, this results from tumours of the bone or soft tissue which secrete FGF 23, causing elevated serum FGF 23 levels and subsequent hypophosphataemia by renal wasting.¹⁵ Typically, this disease presents insidiously with progressive weakness, bone and muscle pain and fractures.¹⁶ This was not tested for in this patient, which is beyond the scope of routine investigation of hypophosphataemia in this setting. However, it should be considered in patients who present with such biochemical findings and a history of non-specific symptoms such as weakness, generalised pain or recurrent fractures and investigated by testing serum FGF 23 levels.

As shown in previously published cases of patients presenting with acute and severe hypophosphataemia, it is often difficult to establish the cause of hypophosphataemia in patients and the cause often remains unknown.⁷

Learning points

- ▶ Hypophosphataemia causes collapse and should be excluded at clinical presentation.
- ▶ Intravenous phosphate should be used to treat patients with severe hypophosphataemia and reduced consciousness.
- ▶ It is important to consider the underlying cause of hypophosphataemia to prevent recurrence.

This case highlights the need for a comprehensive history, examination and biochemistry in the assessment of patients who present to ED with collapse, as such electrolyte disorders are easily reversible. Subsequent workup to determine the cause of hypophosphataemia should also occur to prevent recurrence and to permit treatment of the underlying disorder.

Contributors DW and NS wrote the manuscript. DP and JS critically reviewed and edited the manuscript. All authors approve the final version for publication.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Rajani AR, Murugesan V, Baslaib FO, *et al.* Mitral valve prolapse and electrolyte abnormality: a dangerous combination for ventricular arrhythmias. *BMJ Case Rep* 2014;2014.
- 2 Kashouty R, Yono N, Al Samara M. Status epilepticus secondary to milk-alkali syndrome induced by hypercalcemia (oral antacids). *Seizure* 2011;20:659–61.
- 3 Ewan SL, Moynihan PC. Cardiac arrest: first presentation of anorexia nervosa. *BMJ Case Rep* 2013;2013.
- 4 Ahee P, Crowe AV. The management of hyperkalaemia in the emergency department. *Emergency Medicine Journal* 2000;17:188–91.
- 5 Toovey OT, Edmond IR, Makris N. Acute severe hyponatraemia secondary to polydipsia and associated herbal remedy use. *BMJ Case Rep* 2016;2016.
- 6 Rego I, Vieira D, Correia F, *et al.* Multiple brain lesions in a young man with hypernatraemia. *Case Rep Child Ment Hosp Chic* 2012;2012.
- 7 Ninan S, Lloyd D, Saraswat M. Hypophosphataemia as a cause of acute confusional state. *BMJ Case Rep* 2012;2012.
- 8 Barbe B, Lejoyeux M, Bouleau JH, *et al.* Visual hallucination related to severe hypophosphataemia. *The Lancet* 1991;338:1083.
- 9 Vanneste J, Hage J. Acute severe hypophosphataemia mimicking wernicke's encephalopathy. *The Lancet* 1986;327:44.
- 10 Silvius SE, Paresthesias PPD. weakness, seizures, and hypophosphatemia in patients receiving hyperalimentation. *Gastroenterology* 1972;62:513–20.
- 11 Lee JL SW, Holliday RL, Linton AL. Hypophosphatemia associated with coma. *CMAJ* 1978;119:143–5.
- 12 Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. *Am J Med* 2005;118:1094–101.
- 13 Imel EA, Econs MJ. Approach to the hypophosphatemic patient. *The Journal of Clinical Endocrinology & Metabolism* 2012;97:696–706.
- 14 White KE, Carn G, Lorenz-Depierreux B, *et al.* Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. *Kidney Int* 2001;60:2079–86.
- 15 Jiang Y, Xia WB, Xing XP, *et al.* Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. *J Bone Miner Res* 2012;27:1967–75.
- 16 Dadonienė J, Miglinas M, Miltiniene D, *et al.* Tumour-induced osteomalacia: a literature review and a case report. *World J Surg Oncol* 2015;14:4.

Copyright 2018 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <http://group.bmj.com/group/rights-licensing/permissions>.
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow